CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 27, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 15, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 13, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the

- BT5528 optimized to have distinct physiochemical and in vivo properties thought to enable more favorable preclinical safety, efficacy profiles than those of an antibody drug conjugate CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 12, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a

- Significant recent progress achieved across pipeline of innovative Bicycle ® - based therapies for oncology and beyond - Dosing underway in Phase I dose escalation of BT5528 in combination with nivolumab - Continued to strengthen corporate leadership with appointment of General Counsel - Cash was

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 6, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ®) technology, today announced that management will present at

- Monotherapy Phase I dose escalation remains ongoing; BT5528 appears well-tolerated as dosing approaches clinically relevant levels - BT5528 is the Company’s first second-generation Bicycle® Toxin Conjugate and targets EphA2, a target for which antibody-based approaches have been unsuccessful

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 23, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Zafar

- Phase I dose escalation completed for BT1718 — RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing complete in second cohort of Phase I dose escalation for BT5528 — all doses administered in Phase I to date appear tolerable - Significant

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 6, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ®) technology, today announced that management will